Literature DB >> 9756921

Activation of cyclin-dependent kinase 2 (Cdk2) in growth-stimulated rat astrocytes. Geranylgeranylated Rho small GTPase(s) are essential for the induction of cyclin E gene expression.

T Tanaka1, I Tatsuno, Y Noguchi, D Uchida, T Oeda, S Narumiya, T Yasuda, H Higashi, M Kitagawa, K Nakayama, Y Saito, A Hirai.   

Abstract

The role of the mevalonate cascade in the control of cell cycle progression in astrocytes has been investigated. Serum stimulation of rat astrocytes in primary culture induces the expression of cyclin E followed by the activation of cyclin-dependent kinase 2 (Cdk2) during G1/S transition. The expression of p27, cyclin D1, and the activities of Cdk4 and Cdk-activating kinase (CAK), composed of Cdk7 and cyclin H, were not affected. Serum did, however, stimulate the expression of 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase mRNA at mid-G1 phase. Moreover, an inhibitor of HMG-CoA reductase, pravastatin, reduced cyclin E expression and Cdk2 activation and caused G1 arrest in the astrocytes. In contrast, mevalonate and its metabolite, geranylgeranylpyrophosphate (GGPP) but not farnesylpyrophosphate (FPP), reversed the inhibitory effects of pravastatin on cyclin E expression and Cdk2 activation and allowed G1/S transition. Rho small GTPase(s) were geranylgeranylated and translocated to membranes in the presence of GGPP during G1/S transition. The effect of GGPP on cyclin E expression was abolished by botulinum C3 exoenzyme, which specifically inactivates Rho. These data indicate that geranylgeranylated Rho small GTPase(s) are essential for the induction of cyclin E expression, Cdk2 activation, and G1/S transition in rat astrocytes.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9756921     DOI: 10.1074/jbc.273.41.26772

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  12 in total

Review 1.  Recent trends in microRNA research into breast cancer with particular focus on the associations between microRNAs and intrinsic subtypes.

Authors:  Sasagu Kurozumi; Yuri Yamaguchi; Masafumi Kurosumi; Miki Ohira; Hiroshi Matsumoto; Jun Horiguchi
Journal:  J Hum Genet       Date:  2016-07-21       Impact factor: 3.172

2.  RacB regulates cytoskeletal function in Dictyostelium spp.

Authors:  Eunkyung Lee; David J Seastone; Ed Harris; James A Cardelli; David A Knecht
Journal:  Eukaryot Cell       Date:  2003-06

3.  The Rho GTPase effector ROCK regulates cyclin A, cyclin D1, and p27Kip1 levels by distinct mechanisms.

Authors:  Daniel R Croft; Michael F Olson
Journal:  Mol Cell Biol       Date:  2006-06       Impact factor: 4.272

4.  Cell cycle control of Schwann cell proliferation: role of cyclin-dependent kinase-2.

Authors:  R Tikoo; G Zanazzi; D Shiffman; J Salzer; M V Chao
Journal:  J Neurosci       Date:  2000-06-15       Impact factor: 6.167

5.  Farnesylcysteine analogues inhibit store-regulated Ca2+ entry in human platelets: evidence for involvement of small GTP-binding proteins and actin cytoskeleton.

Authors:  J A Rosado; S O Sage
Journal:  Biochem J       Date:  2000-04-01       Impact factor: 3.857

6.  Effects of lovastatin and pravastatin on amyloid processing and inflammatory response in TgCRND8 brain.

Authors:  Neelima B Chauhan; George J Siegel; Douglas L Feinstein
Journal:  Neurochem Res       Date:  2004-10       Impact factor: 3.996

7.  Geranylgeranyl-pyrophosphate, an isoprenoid of mevalonate cascade, is a critical compound for rat primary cultured cortical neurons to protect the cell death induced by 3-hydroxy-3-methylglutaryl-CoA reductase inhibition.

Authors:  T Tanaka; I Tatsuno; D Uchida; I Moroo; H Morio; S Nakamura; Y Noguchi; T Yasuda; M Kitagawa; Y Saito; A Hirai
Journal:  J Neurosci       Date:  2000-04-15       Impact factor: 6.167

8.  SUMOylation of RhoGDIα is required for its repression of cyclin D1 expression and anchorage-independent growth of cancer cells.

Authors:  Zipeng Cao; Xueyong Li; Jingxia Li; Beipei Kang; Jingyuan Chen; Wenjing Luo; Chuanshu Huang
Journal:  Mol Oncol       Date:  2013-12-03       Impact factor: 6.603

Review 9.  Multifunctional drug treatment in neurotrauma.

Authors:  Bogdan Stoica; Kimberly Byrnes; Alan I Faden
Journal:  Neurotherapeutics       Date:  2009-01       Impact factor: 7.620

10.  ER, PgR, Ki67, p27(Kip1), and histological grade as predictors of pathological complete response in patients with HER2-positive breast cancer receiving neoadjuvant chemotherapy using taxanes followed by fluorouracil, epirubicin, and cyclophosphamide concomitant with trastuzumab.

Authors:  Sasagu Kurozumi; Kenichi Inoue; Hiroyuki Takei; Hiroshi Matsumoto; Masafumi Kurosumi; Jun Horiguchi; Izumi Takeyoshi; Tetsunari Oyama
Journal:  BMC Cancer       Date:  2015-09-07       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.